National Research (NRC)
(Delayed Data from NSDQ)
$14.80 USD
-1.09 (-6.86%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $14.78 -0.02 (-0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NRC 14.80 -1.09(-6.86%)
Will NRC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRC
NRC's Q2 Earnings Rise Y/Y on Cost Control and TRCV Growth
NRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13%
NRC: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research
Top Stock Reports for Philip Morris, Booking Holdings & Anheuser-Busch
National Research's Q4 Earnings Drop Y/Y, Stock Falls 9%
Other News for NRC
Non-ADX 1,2,3,4 Bullish appears for NRC after 0.13% move
The technical outlook for NRC is unchanged after it falls 0.93% on September 17
Neuronetics announces New York State Medicaid to begin covering TMS services
NR7 appears for NRC after 0.86% move
The technical outlook for NRC is unchanged after it rises 1.19% on September 15